103,720 Shares in Tyra Biosciences, Inc. $TYRA Bought by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon bought 103,720 shares of Tyra Biosciences in the second quarter, worth approximately $3.3 million. Institutional investors collectively own 84.14% of the company.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $48.22; twelve analysts rate the stock Buy, compared with one Hold and one Sell.
• Tyra shares opened at $28.65, well below their 52-week high of $40.65. The company reported a quarterly loss of $0.69 per share, missing estimates by $0.04, and analysts expect a full-year loss of $2.74 per share.

Bank of New York Mellon Corp purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 103,720 shares of the company's stock, valued at approximately $3,313,000. Bank of New York Mellon Corp owned about 0.17% of Tyra Biosciences as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TYRA. Hilton Head Capital Partners LLC bought a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in Tyra Biosciences during the 4th quarter worth approximately $51,000. State of Wyoming purchased a new position in Tyra Biosciences in the 2nd quarter worth approximately $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock worth $126,000 after purchasing an additional 1,668 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company's stock valued at $178,000 after purchasing an additional 2,766 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TYRA has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Tyra Biosciences in a research report on Friday. Wolfe Research began coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a "peer perform" rating for the company. Jefferies Financial Group reiterated a "buy" rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Bank of America boosted their target price on Tyra Biosciences from $37.00 to $42.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Finally, JonesTrading began coverage on Tyra Biosciences in a report on Wednesday, June 17th. They set a "buy" rating and a $56.00 target price for the company. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tyra Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $48.22.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA opened at $28.65 on Monday. Tyra Biosciences, Inc. has a 1 year low of $11.70 and a 1 year high of $40.65. The firm has a 50-day moving average of $29.02 and a 200 day moving average of $32.05. The stock has a market cap of $1.71 billion, a P/E ratio of -11.94 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.04). Research analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.